Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | ADH1B | P00325 | 1/20 | 0.42 |
| ▸ | ADH1C | P00326 | 1/20 | 0.42 |
| ▸ | ADH1A | P07327 | 1/20 | 0.42 |
| ▸ | ADH4 | P08319 | 1/20 | 0.42 |
| ▸ | ADH7 | P40394 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.39 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22493178 | 1.00 | ACE2 (0.45) | ACE2EPHX1OPRM1ADH1BADH1C | |
| SCHEMBL29303870 | 1.00 | ACE2 (0.45) | ACE2EPHX1OPRM1ADH1BADH1C | |
| SCHEMBL18591106 | 1.00 | ACE2 (0.45) | ACE2EPHX1OPRM1ADH1BADH1C | |
| SCHEMBL30686660 | 1.00 | ACE2 (0.45) | ACE2EPHX1OPRM1ADH1BADH1C | |
| SCHEMBL27333651 | 1.00 | ACE2 (0.45) | ACE2EPHX1OPRM1ADH1BADH1C | |
| SCHEMBL14307876 | 1.00 | ACE2 (0.45) | ACE2EPHX1OPRM1ADH1BADH1C | |
| SCHEMBL21298785 | 1.00 | ACE2 (0.45) | ACE2EPHX1OPRM1ADH1BADH1C | |
| SCHEMBL20776359 | 1.00 | ACE2 (0.45) | ACE2EPHX1OPRM1ADH1BADH1C | |
| SCHEMBL13474807 | 0.98 | OPRM1 (0.44) | ACE2EPHX1OPRM1ADH1BADH1C | |
| SCHEMBL13443141 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707457-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11026979-B2 | Human hepatocytes and uses thereof | ACCELERATED BIOSCIENCES CORP. (US) | 2021-06-08 | — | — | US | disclosed |
| WO-2021072330-A1 | GALNAC-TGFBR1 INHIBITOR CONJUGATES FOR THE TREATMENT OF LIVER DISEASES | SILVERBACK THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20200345788-A1 | HUMAN HEPATOCYTES AND USES THEREOF | ACCELERATED BIOSCIENCES CORP. | 2020-11-05 | — | — | US | disclosed |
| EP-3240408-B1 | PICOLINAMIDES WITH FUNGICIDAL ACTIVITY | DOW AGROSCIENCES LLC (US) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018086605-A1 | NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 山东罗欣药业集团股份有限公司 | 2018-05-17 | — | — | WO | disclosed |
| EP-1790639-B1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS CXCR4-ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2014-03-26 | — | — | EP | disclosed |
| WO-2014037340-A1 | USE OF SUBSTITUTED 2-AMIDOBENZIMIDAZOLES, 2-AMIDOBENZOXAZOLES AND 2-AMIDOBENZOTHIAZOLES OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2014-03-13 | — | — | WO | disclosed |
| US-5484949-A | Method for the synthesis of α β-unsaturated ketones | NIPPON SODA CO., LTD. (JP) | 1996-01-16 | — | — | US | disclosed |
| EP-0454867-A1 | A METHOD FOR THE SYNTHESIS OF -g(a), -g(b)-UNSATURATED KETONES. | NIPPON SODA CO (JP) | 1991-11-06 | — | — | EP | disclosed |
| WO-1991007370-A1 | A METHOD FOR THE SYNTHESIS OF α, β-UNSATURATED KETONES | NIPPON SODA CO., LTD. (JP) | 1991-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707457-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ACE2 558/4885EPHX1 1684/4885OPRM1 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.